In the metastatic setting, the IMpassion130 trial showed a 7 month improvement in OS when the PD-L1 inhibitor atezolizumab was added to nab-paclitaxel chemotherapy in the front line setting for patients with TNBC and positive expression of PD-L1 on the immune cells within the tumor microenvironment [17, 18]. The gene discussed is CD274; the disease is neoplasm.